Research programme: anti-nucleosome antibodies - Ambrilia Biopharma
Alternative Names: ANA; ANAs research programme - Procyon; ANsA research programme - Procyon; Anti-nucleosome antibodies research programme - Procyon; Monoclonal antibody 2C5Latest Information Update: 24 Oct 2021
At a glance
- Originator Ambrilia Biopharma
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 09 Jul 2013 Discontinued - Preclinical for Cancer in Canada prior to 9 July 2013 (parenteral)
- 09 Jul 2013 Discontinued - Preclinical for Cancer in United Kingdom prior to 9 July 2013 (parenteral)
- 03 Mar 2006 Cellpep has merged with Procyon Biopharma to form Ambrilia Biopharma